Chimeric Antigen Receptor T-cell Therapy

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

The decision rests on phase 2 data showing high response rates with labeling that highlights cytokine release syndrome and neurologic risks.